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Abstract: Regulation of the SLC12 family of membrane transporters including NCCT involves a scaffold of interacting 
proteins including the STE 20 kinase SPAK and the WNK kinases, WNK 1 and WNK 4, which are mutated in the 
hypertensive syndrome of pseudohypoaldosteronism type 2 (PHAII). WNK4 regulates NCCT by affecting forward 
trafficking to the surface membrane. Studies in Xenopus using kinase dead WNK4 site mutants have produced 
inconsistent results with regard to the necessity of kinase function for NCCT regulation. Dynamic inhibition of WNK4 by 
small molecules may bring clarity to this issue however WNK4 is naturally resistant to commercial MAP kinase inhibitors 
owing to steric constraints prohibiting entry of small molecules to the active site. Using an approach similar to that used in 
p38 and ERK, we show that a single substitution in WNK4 (T261G) dramatically enhances its susceptibility to the 
inhibitors SB 202190 and SB 203580. 
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INTRODUCTION 
Protein kinases form a fundamental network of 
intracellular signalling molecules necessary for most human 
signal transduction pathways. Abnormal kinase function has 
been associated with disease processes as diverse as cancer 
[1], diabetes [2], rheumatoid arthritis [3] and hypertension 
[4]. Recent therapeutic advances using small cell permeable 
kinase inhibitors have yielded dramatic results; for example 
the BCR-ABL inhibitor Imatinib, effective in Chronic 
Myeloid leukaemia [5] and the mTOR inhibitor Rapamycin 
for preventing transplant rejection [6] and have also 
revolutionised our understanding of signal transduction 
pathways themselves [7]. 
Kinases may contribute to hypertension either by 
augmenting arteriolar vasoconstriction by Rho kinase [8] or 
by increasing sodium retention in the distal renal tubule 
through regulation of ENaC by SGK1 [9] and NCCT by 
WNK kinases [4]. WNK kinases (With No Lysine Kinases) 
are a family of four kinases of which the genes for WNK1 
and WNK4 are mutated in Gordon syndrome or Pseudohy- 
poaldosteronism type II (PHA II), a rare monogenic form of 
hypertension. A model in which WNK1 inhibits WNK4 that 
in turn inhibits NCCT forward trafficking to the apical 
membrane is well established [4], although the effect of 
WNK4 kinase function in regulating NCCT expressed in 
Xenopus using kinase dead site mutants has yielded 
inconsistent results [10-12]. A major limitation in the 
exploration of WNK kinase function in Xenopus as well as in 
tissues and whole animals has been the absence of specific 
inhibitors. 
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The pyridinyl imidazoles SB 203580 and SB  202190 
were developed at SmithKline Beecham as inhibitors of IL-1 
and TNF production in activated monocytes [13]. 
Radioligand binding assay subsequently identified the kinase 
targets now known as the stress activated MAPK kinases, 
SAPK2a/p38 and SAPK2b/p38. These SB compounds 
were used to elucidate some of the physiological effects of 
this pathway [14], as well as identifying downstream targets 
of the kinases [14-16]. X-ray crystallography of SB 203580 
bound to p38 kinase revealed the drug binding to the ATP 
binding pocket and allowed adjacent residues in the pocket 
to be identified [17]. Threonine
106 is located close to the 4-
fluorophenyl ring of the inhibitor Fig. (1) and mutation to the 
more bulky M
106 retards kinase inhibition [14, 17, 18]. In 
fact, a series of T106 p38 mutants showed a hierarchy of 
kinase inhibition with smaller residues such as glycine or 
alanine allowing maximum drug binding. Using this 
approach a previously insensitive kinase, ERK 2, was made 
drug-sensitive by mutation of the homologous residue Q105 
to the smaller T105 [19]. Four other closely located residues 
were also found to modulate ERK2 sensitivity to SB 203580 
in a complementary manner.  
We hypothesised that in WNK4, mutation of the 
homologous amino acid T261 to glycine might facilitate 
binding of small molecule kinase inhibitors such as the SB 
compounds to the ATP pocket and so confer drug sensitivity 
permitting dynamic investigation of WNK4 kinase function 
on the regulation of NCCT.  
MATERIALS AND METHADOLOGY 
Cloning and cRNA Synthesis 
Wild type NCCT in ECFP-TNT with cyan fluorescent 
protein at its N terminal and wild type WNK4 in pcDNA3 
were as previously described [11]. The WNK4 cDNA was 
mutated to T261G using site directed mutagenesis 58    The Open Medicinal Chemistry Journal, 2010, Volume 4  Glover et al. 
(Stratagene, La Jolla, CA). All sequences were verified using 
an ABI 377 and Big Dye fluorescent chemistry (Applied 
Biosystems, Foster City, CA). Copy RNA was transcribed in 
vitro from linearized plasmids using the T7 mMESSAGE 
mMACHINE
®
 kit (Ambion, Austin, Tx) and quantified using 
ultraviolet absorption spectroscopy (Nanodrop, Wilmington, 
DE). 
Expression in Xenopus Oocytes 
Xenopus laevis oocytes were harvested and defolliculated 
as detailed previously [20]. Briefly, 10 ng of NCCT cRNA 
was injected in a total volume of 50nl per oocyte, and for 
coinjections involving WNK4 an additional 10ng cRNA was 
added to the injectate. RNAase and DNAase free water-
injected oocytes were used as controls throughout. Oocytes 
were then incubated in ND96 containing 2 mM sodium 
pyruvate, 0.1mg/ml gentamicin and kinase or inhibitors at 
18
oC for 5 days. 
For 
22Na
+ flux studies, oocytes were placed for 24 hours 
in Cl
- free ND96 solution containing 96mM sodium 
isethionate, 2mM potassium gluconate, 1.8 mM calcium 
gluconate, 1mM magnesium gluconate, 5mM HEPES, 
2.5mM sodium pyruvate and 5mg/dl gentamicin. Thirty 
minutes before the addition of uptake medium, oocytes were 
added to Cl
- free ND96 with inhibitors (1mM ouabain, 
100M amiloride and 100M bumetanide) according to the 
protocol of Gamba [21] . Oocytes were then transferred to 
isotonic uptake medium (58mM NaCl, 38mM M-methyl-D-
glucamine, 2mM KCl, 1.8mM CaCl2 and 5mM HEPES with 
inhibitors pH 7.4) containing 
22Na
+ at a final concentration of 
2.5Ci/ml and incubated in a gently shaking incubator at 
37
oC for 1 hour. Oocytes were then washed five times with 
3ml ice cold aliquots of isotonic medium and the oocytes 
counted individually in a gamma counter (Perkin-Elmer 
Cobra 5003). Thiazide sensitivity was confirmed using 
100M hydrochlorthiazide (data not shown). 
Membrane surface expression measurements were 
performed 5 days after injection by laser-scanning confocal 
microscopy with a Leica DMRXA confocal microscope. 
Data was captured using an equatorial section through each 
oocyte under a x10 objective lens with brightness, contrast 
and pin-hole settings kept constant for all oocytes in each 
injection series. The fluorescent signal in the membrane was 
quantified using Leica confocal software (version 2.61 of 
LCS Lite
®) with sampling made at sixteen equispaced points 
on the circumference and averaged to give mean total 
fluorescence intensity in arbitrary fluorescence units (AFUs). 
Data Analysis 
For all oocyte experiments ten to fifteen oocytes were 
injected for each cRNA used. Differences between groups 
were compared by 1-way ANOVA with post hoc testing. 
Figures show representative experiments that were replicated 
using at least four different batches of oocytes from different 
donor animals. The SPSS statistical package (software 
version 12) was used throughout with significance defined as 
P < 0.05. The IC50 values for the SB compounds were 
derived from the fitting of the dose-response curves to a 
simple logistic function using GraphPad version 4. 
RESULTS 
T261G Mutant WNK4 Behaves as Wild Type WNK4 
22Na
+ flux measurable in NCCT injected oocytes was 
completely inhibited by hydrochlorothiazide (100 μM) as 
shown in Fig. (2A).  Wild type WNK4 coinjection with 
NCCT decreased 
22Na
+ uptake by 62% (3.0 +/- 0.1 vs. 7.9 
+/- 0.4 nmol/oocyte/h, P<10
-4) in keeping with previous 
reports.  T261G WNK4 produced a similar effect reducing 
22Na
+ uptake through NCCT by 71% (2.3 +/- 0.4 vs. 7.9 +/- 
0.4 nmol/ oocyte/h, P< 10
-4), which was not significantly 
different from wild type WNK4 (3.0 +/- 0.1 vs. 2.3 +/- 0.4 
nmol/oocyte/h, P> 0.05). 
Confocal microscopy of ECFP-NCCT injected oocytes 
showed that WNK4 effects on NCCT flux activity were 
accompanied by parallel changes in surface membrane 
expression of the transporter Fig. (2B).  Wild type WNK4 
decreased membrane expression of ECFP-NCCT by 52% 
(14.1 +/- 1.1 vs. 29.4 +/- 2.6 AFUs, P<  10
-4). Similarly 
T261G WNK4 reduced NCCT surface membrane abundance 
by 41% (17.2 +/- 1.8 vs. 29.4 +/- 2.6 AFUs, P< 10
-4). Again 
the effects of the two forms of WNK4 kinases were   
not significantly different from each other (14.1 +/- 1.1 vs. 
17.2 +/- 1.8 AFU’s, P >0.05). 
Site Mutation of WNK4 Confers Kinase Inhibitor 
Sensitivity 
Xenopus oocytes were injected with cDNA for ECFP-
NCCT with either wild type or the mutant WNK4 T261G. 
They were then incubated with low (0.5 M) or high (5M) 
concentrations of the SB compounds to see if these kinase 
inhibitors were able to block the catalytic activity of WNK4 
and restore 
22Na
+ uptake. Fig. (3A) shows that 
22Na
+ uptake 
by  wild type WNK4 injected oocytes was unaffected by 
incubation with either concentration of the SB inhibitors 
indicating that the IC50 for both SB compounds must be >5 
M against wild type WNK4. Conversely 
22Na
+ flux through 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Chemical structure of the p38 kinase inhibitors SB202190 and SB 203580. 
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NCCT coinjected with mutant WNK4 T261G was increased 
when incubated with either inhibitor; the flux actually return-
ing to the level seen in oocytes injected with NCCT alone.  
The changes in 
22Na
+ flux, were accompanied by parallel 
changes in the membrane fluorescence and hence membrane 
expression of NCCT Fig. (3B).  
Concentration Response Curves for SB 202190 and SB 
203580 
These results in Fig. (3) suggested that the IC50 for both 
SB compounds was at ~100-fold lower for the T261G mutant 
versus  wild type. To confirm this, concentration-response 
curves were generated for the SB compounds in oocytes 
expressing WNK4 T216G. The fitted IC50 values were 109 
nM for SB 203580 and 147 nM for SB 202190 Fig. (4). 
DISCUSSION AND CONCLUSION 
Experiments to study the effects of WNK4 in whole 
animals and tissues have been hampered by the lack of an 
inhibitor. Although it is well established that wild type 
WNK4 inhibits NCCT forward trafficking to the surface 
membrane [4], it was unclear whether in tact kinase function 
was necessary for this to occur. Studies using kinase dead 
WNK4 site mutants expressed in Xenopus have yielded 
inconsistent results [10-12]. 
 
 
 
 
 
 
Fig. (2). The T261G WNK4 mutant behaves like wild type WNK4. 
A. Oocytes were injected with NCCT wt alone or in combination 
with WNK4 wt or WNK4 T261G. Mutant WNK4 reduced 
22Na
+ 
flux equivalent to the same extent as WNK4 wt. * P< 0.0001vs 
NCCT alone. B. Confocal microscopy of the fluorescent signal 
from eCFP-NCCT showed that changes in WNK4 induced 
22Na
+ 
flux were accompanied by similar changes in surface membrane 
expression
 of the cotransporter. * P< 0.0001 vs NCCT alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). The T261G mutation of WNK4 confers kinase inhibitor 
sensitivity. A. Oocytes were injected with NCCT wt alone or in 
combination with either WNK4 wt or WNK4 T261G. The 
22Na
+ 
flux assay was then performed with or without 0.5 or 5 M of each 
SB compound. * P<0.0001 vs NCCT alone. B. Confocal 
microscopy of the fluorescent signal from eCFP-NCCT showed 
that changes WNK4-induced 
22Na
+  flux were accompanied by 
parallel changes in surface membrane expression
  of the 
cotransporter. * P< 0.05 vs assay without an SB inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H2O 
NCCT
+ HCT
+ WNK4 wt
+ WNK4 T261G
0
1
2
3
4
5
6
7
8
H2O 
NCCT 
+ WNK4 wt
+ WNK4 T261G
0
5
10
15
20
25
30
35
*
*
F
l
u
o
r
e
s
c
e
n
c
e
 
(
A
F
U
s
)
A
B
H2O 
NCCT
+ WNK4 wt
M SB202190
m
m m m
+ WNK4 wt + 5
M SB203580
m
m m m
+ WNK4 wt + 5
+ WNK4 T261G
M SB202190
m
m m m
+ WNK4 T261G + 0.5 M SB 203580
m
m m m
+ WNK4 T261G + 0.5
0.0
2.5
5.0
7.5
H2O 
NCCT 
+ WNK4 wt
M SB202190
m
m m m
+ WNK4 wt + 5 
M SB203580
m
m m m
+ WNK4 wt + 5  + WNK4 T261G
M SB 202190
m
m m m
+ WNK4 T261G + 0.5
M SB 203580
m
m m m
+ WNK4 T261G + 0.5
0
10
20
30
40 ** **
F
l
u
o
r
e
s
c
e
n
c
e
 
(
A
F
U
s
)
A
B60    The Open Medicinal Chemistry Journal, 2010, Volume 4  Glover et al. 
Within the kinome, the WNKs show closest homology to 
the MAPKK subgroup of MAPK kinases. Inhibitors of the 
MAPK kinase family are well described, although the 
sensitivity of individual kinases is dependent on steric 
factors around the ATP binding pocket. In keeping with 
reports using p38 and ERK2 kinases [14-16, 19], we found 
that mutation of the single threonine residue at position 
261of WNK4 (homologous amino acid 106 in p38) to a 
residue with a much smaller side chain resulted in dramatic 
enhancement of its sensitivity to SB 202190 and SB203580. 
The IC50 for both agents shifted from >5000 nM to ~100 
nM, so that both inhibitors were able to completely reverse 
the effect of WNK4 T261G on NCCT in the oocyte system. 
These results confirm that WNK4 requires a catalytically 
intact kinase function to affect NCCT trafficking [10, 11]. 
It is hoped that further study of the steric constraints 
preventing small molecules from gaining access to the active 
site of WNK kinases may enable the design of compounds 
capable of inhibiting wild type WNK kinases. The 
availability of small molecule inhibitors of wild type WNK4 
may be attractive therapeutically. Salt-retention through 
increased expression of NCCT could be useful, for example, 
in hypotensive states such as autonomic failure. It is not 
clear that a similar strategy could be used for WNK1. 
Heterozygous mouse knock-outs for WNK1 do have a 
lowered blood pressure [22], but there are contradictory 
reports of the necessity for intact WNK1 kinase function to 
influence NCCT via WNK4 [11, 12]. WNK1 is also found 
predominantly in the short form which lacks the kinase 
domain [23], although in states of low potassium diet [24] or 
Gordon syndrome, the full length transcript may be 
physiologically more significant [25, 26].  
In summary, we have shown that T261G mutation of 
WNK4 renders it susceptible to inhibition by SB202190 and 
SB203580 and confirming that the ability of WNK4 to 
regulate NCCT is indeed dependent on kinase activity. This 
may be useful in elucidating the role of WNK4 kinase activity 
in regulating renal electrolyte transport experimentally. 
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